News
TRVI
1.800
+0.56%
0.010
SVB Securities Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)
TipRanks · 21h ago
Needham Keeps Their Buy Rating on Trevi Therapeutics (TRVI)
TipRanks · 3d ago
Trevi Therapeutics (TRVI) Initiated with a Buy at JonesTrading
TipRanks · 3d ago
JonesTrading Keeps Their Buy Rating on Trevi Therapeutics (TRVI)
TipRanks · 3d ago
Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Benzinga · 4d ago
BRIEF-Trevi Therapeutics Announces Fourth Quarter And Year End 2022 Financial Results And Provides Business Update
Reuters · 4d ago
Trevi Therapeutics Q4 EPS $(0.06) Beats $(0.10) Estimate
Benzinga · 4d ago
Trevi Therapeutics GAAP EPS of -$0.06 beats by $0.03
Seeking Alpha · 4d ago
Earnings Scheduled For March 16, 2023
Benzinga · 4d ago
Earnings Outlook For Trevi Therapeutics
Benzinga · 5d ago
JonesTrading Initiates Coverage of Trevi Therapeutics (TRVI) with Buy Recommendation
NASDAQ · 6d ago
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Benzinga · 6d ago
--JonesTrading Initiates Trevi Therapeutics at Buy With $7 Price Target
--JonesTrading Initiates Trevi Therapeutics at Buy With $7 Price Target
MT Newswires · 03/14 09:57
Woodside Energy, New Oriental Education & Technology, Weibo among premarket losers' pack
Seeking Alpha · 03/08 13:46
BRIEF-Trevi Therapeutics Reports Notice Of Allowance For U.S. Patent Application Covering Use Of Haduvio (nalbuphine ER)
Reuters · 03/08 12:46
Trevi stock rises on upcoming US patent for chronic cough drug Haduvio
Seeking Alpha · 03/08 12:45
Trevi Therapeutics Gets Patent Notice of Allowance for Method to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis
Trevi Therapeutics Gets Patent Notice of Allowance for Method to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis
MT Newswires · 03/08 11:47
BRIEF-Trevi Therapeutics Provides Business Update Ahead Of Upcoming Conferences
Reuters · 01/05 21:08
Organigram And Rounding Out My Tax Loss Selling Basket
Seeking Alpha · 01/02 12:07
More
Webull provides a variety of real-time TRVI stock news. You can receive the latest news about Trevi Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat neurologically mediated conditions. It is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. It is conducting Phase IIb/3 clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It is also conducting Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as Phase II CANAL trial. It has also commenced Phase Ib trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio. Its Haduvio development programs include Active Chronic Pruritus Programs, Prurigo Nodularis Program, and Chronic Cough in Idiopathic Pulmonary Fibrosis Program.